CAMECO CORPORATION [CCJ]
Sector: Nuclear
Sub-industry: Uranium mining + integrated fuel cycle (via Westinghouse)
Market Cap: $46.8B

All figures as of May 15, 2026 close. Source: Cameco MD&A, Q1'26 release, TradeTech / UxC weekly indicators.

Most retail nuclear conversations stop at the reactor operators — Constellation Energy (CEG), Vistra (VST), Talen Energy (TLN). The names that turn power prices into earnings. That framing misses where the real scarcity sits.

Cameco does three things, and only one of them is "mine uranium."

Through majority-owned operations at Cigar Lake (54.5% interest, the world's highest-grade uranium mine) and McArthur River / Key Lake (70%, the world's largest high-grade mine), Cameco produces concentrate from the only meaningful tier-one resource base outside Kazakhstan and Russia. At Port Hope it converts that concentrate into UF₆ — the form utilities actually buy — at one of two non-Chinese conversion facilities operating in the West. And through a 49% stake in Westinghouse Electric Company (Brookfield holds the other 51%, deal closed November 2023), Cameco owns roughly half of the OEM that builds the AP1000 reactor, fabricates fuel for ~50% of the non-Russian, non-Chinese reactor fleet, and runs the largest Western reactor-services franchise.

No other Western public company touches five of the seven stages of the nuclear fuel cycle. Russia's Rosatom does — which is the entire reason Cameco trades the way it does.

That integration is the investment thesis. It is also the reason the equity has rerated from $50 a year ago to a $135 high inside twelve months — and why a sober reading of today's price is the question we want to answer.

The Monday teaser said consensus is discounting the wrong cycle. We want to be precise about what that means.

The street is overwhelmingly bullish on Cameco. Fifteen analysts at Moderate Buy. Average twelve-month price target near $150, range $130 to $185. Bernstein named Cameco a top energy pick into 2026. The shared view: tier-one uranium leverage plus Westinghouse plus the AP1000 program equals a generational compounder.

We share the structural view. Where we differ is on the cycle being priced.

Cameco's earnings come from three engines. A uranium book where realized prices are climbing as legacy fixed-price contracts roll into a $66/lb realized today against a $88/lb long-term market reference. A fuel-services business that scales with conversion and CANDU fuel scarcity. And a Westinghouse share where recurring services revenue compounds while AP1000 new-build sits as option value.

The first two engines are cyclical. They compound at single-digit to low-teen rates as contracts re-price and as fleet services renew. The third engine — AP1000 new-build under the $80 billion US government partnership announced last October — is exponential if it happens. The market is pricing CCJ at 62× forward earnings and 22× EBITDA. That multiple implies the third engine works. It implies roughly 60% confidence in a smooth $80 billion execution.

The historical base rate for large US nuclear programs slipping their original timeline is closer to 70%.

That is the cycle being mis-discounted. Not the magnitude. The probability.

Cameco's Q1 2026 was consistent with the multi-quarter trend.

Uranium segment sales hit 7.8 million pounds at an average realized price of US$66.21/lb — up 18% year-on-year. Spot uranium now trades at $86; the long-term reference is $88. The gap between Cameco's realized price and the market is mechanical: legacy fixed-price contracts signed when uranium traded between $25 and $50/lb continue to roll off the book. Each year another 5-7 million pounds re-prices into the market-related contract structure. Uranium segment EBITDA margin came in near 70%.

The contracted book stands at roughly 230 million pounds committed at an average of 28 million pounds per year through 2030, weighted heavier in 2026-2028. In March, Cameco signed a 22 million pound, US$2.6 billion, nine-year supply agreement with India. The 2025 Slovenské elektrárne UF₆ deal continues to deliver. Long-running CNNC and EDF relationships continue. No single customer represents more than 10% of revenue.

Cash conversion was lumpy — Q1 cash flow from operations ran modestly negative on inventory build and tax timing — but the underlying engine is steady. The story is in the realized-price trajectory, and that trajectory is intact.

This is the section that defines Cameco's variance from peers.

Westinghouse Electric Company is the dominant Western nuclear technology platform. Underlying revenue runs near US$8 billion annually, with roughly 30% from new reactor builds and 70% from recurring fuel and services. Cameco's 49% share delivered approximately C$620 million in EBITDA in 2025 — about 33% of Cameco's reported total. Management guided 6-10% core EBITDA growth at Westinghouse over five years, before any AP1000 new-build cash distributions.

The new-build piece is the option.

In October 2025, Westinghouse announced an $80 billion partnership with the US government to deploy AP1000 reactors. No final investment decisions yet — the structure is a sequence of memoranda of understanding with potential utility partners. The first FID could land anywhere between mid-2026 and late 2027. The Czechia Dukovany contract signed in 2024 — and the resulting cash distribution to Westinghouse partners in 2025 — provides the template for how new-build flows to Cameco's bottom line when it works.

Where we land on the sum-of-the-parts at FY2027E numbers: the uranium business carries roughly C$17.5 billion at a 14× EBITDA multiple (a premium to mining peers, justified by tier-one quality). Fuel services adds roughly C$3 billion at 12×. Westinghouse's core recurring business at the Cameco share carries approximately C$9 billion at 15× — which implies a 100% Westinghouse enterprise value of around US$13.5 billion, within range of the US$7.9 billion paid for the 49% stake in 2023. Add net cash and the Canada Revenue Agency tax-dispute recovery.

Total enterprise value lands at C$33-36 billion. Per share, US$55-60.

That figure includes no AP1000 new-build option value. Today's stock price requires at least US$6 billion of new-build option value to clear. That is possible. It is not certain.

A deep dive that only showed tailwinds would not be analysis. It would be marketing.

Cameco does not value cleanly on a single multiple.

The uranium business is a long-duration, contract-priced franchise with optionality on spot. Westinghouse is a private equity-method investment whose new-build component cannot be falsifiably modeled for five-plus years. We triangulate.

On peer comparison: CCJ trades at 22× FY26E EBITDA and 15× FY26E sales — top of the mining equity universe. Kazatomprom (KAP) trades at 7× EBITDA. Uranium Energy Corp (UEC) at ~25× sales (smaller cap, US-domiciled premium). NexGen Energy (NXE) is pre-revenue option-value on the Arrow deposit. The CCJ premium is for Westinghouse plus tier-one quality plus non-Russian leverage. The premium is real. So is the premium.

On reverse DCF: today's price implies 9.5% free cash flow CAGR through 2035, assuming a 9% WACC and 2.5% terminal growth. Cameco's 2021-25 revenue CAGR ran at 24%, but most of that came from margin expansion, not volume. Sustaining 9.5% FCF growth for a decade requires both volume and price to keep compounding.

On scenario weighting: 25% bull case at $175 (AP1000 FID lands by year-end 2026, U₃O₈ breaks $110), 50% base at $115 (guidance met, modest uranium upside), 25% bear at $65 (flooding extends, U₃O₈ retraces). Probability-weighted twelve-month fair value: roughly $117.

That implies 9% expected return from $107 before dividend. The asymmetry inverts favorably below $85.

This is the section that matters.

Cameco is the highest-quality liquid expression of the Western nuclear fuel cycle. The integration is real. The tier-one resources are irreplaceable. Westinghouse changes the company from a uranium miner into something closer to a vertically integrated nuclear utility-services compounder. Monday's teaser called it the only single ticker that lets you own the entire fuel cycle. That framing remains accurate.

At $107, the market is paying the full bill.

Our variant view is not contrarian on the thesis — the nuclear renaissance is real and Cameco is the cleanest Western expression of it. The variant is on timing and price. The market treats CCJ as a long-duration growth compounder and prices it at 62× forward earnings. Two of the three EBITDA legs — uranium realized-price catch-up and Westinghouse core services — are cyclical, not exponential. They compound at single-digit to low-teen rates. The third leg, AP1000 new-build, is exponential if it happens. The market is pricing that third leg as if smooth $80 billion execution were a 60%+ probability. The historical base rate for large US nuclear programs slipping their original timeline is closer to 70%.

The bull case is that the $80B program announces its first FIDs by year-end 2026 and CCJ trades to $175 or above. The bear case is that Saskatchewan flooding extends, U₃O₈ retraces on Russian normalization, and the multiple compresses to ~15× EBITDA — taking the equity to $65 or below. Both are plausible. At $107 the upside-to-downside skew is unfavorable.

Five things that resolve the variant view in the next twelve months.

If this was useful, forward it to one person who'd find it valuable.
Follow us on X @TerawattEra for daily commentary between editions.
Next Monday: We will cover the week's most consequential developments across grid, renewables, nuclear, and LNG.

Terawatt Era is for informational purposes only. Nothing in this publication constitutes investment, legal, or tax advice, and nothing here is a solicitation, recommendation, or offer to buy or sell any security or financial instrument.

Terawatt Era is published from British Columbia, Canada, as general-circulation financial commentary. It is not registered as an investment adviser, dealer, or in any other capacity under the BC Securities Act, the United States Investment Advisers Act of 1940, or the securities laws of any other jurisdiction, and is intended to fall within the publisher / media exemption from adviser registration requirements in applicable jurisdictions. Nothing in this publication is, or should be construed as, advice directed at any specific person or tailored to any reader's individual circumstances, financial situation, or investment objectives.

The information and analysis in this edition are drawn from sources believed to be reliable — including public filings, company disclosures, trade press, and third-party research — but Terawatt Era makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information presented. Estimates, forecasts, scenarios, and editorial views reflect our judgment as of the publication date and are subject to change without notice. They may prove to be wrong.

Past performance does not guarantee future results. All investments involve risk, including the risk of loss of principal. Readers should conduct their own research and consult appropriately qualified professionals in their jurisdiction before making any investment decision.

The author may hold positions in securities mentioned and reserves the right to change those positions at any time without notice. Terawatt Era receives no compensation from companies covered in this publication.

Copyright © 2026 Terawatt Era · terawattera.com